Skip to main content

MAP2K1 Gene Alteration clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for
  • Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

    open to eligible people ages 18 years and up

    This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.

    at UCSD

Last updated: